Researchers have discovered a new way in which RAS genes, which are commonly mutated in cancer, may drive tumor growth beyond their well-known role in signaling at the cell surface. Mutant RAS, they ...

New clinical data from Phase 1 trial of ZW191 to be presented in an oral presentation on April 21Preclinical data highlight combination potential ...

Researchers at the Francis Crick Institute and Vividion Therapeutics have identified chemical compounds that can precisely block the interaction between the major cancer-driving gene RAS and a key ...

A blue protein ribbon structure labeled PI3Kα has a space-filling molecule bound to it, which interacts (clashes) with a second protein ribbon molecule labeled KRas. This model shows how BBO-10203 ...

RAS genes are the second most frequently mutated genes in cancer, and mutant RAS proteins are key drivers of some of the deadliest cancers, including nearly all pancreatic cancers, half of colorectal ...

New research from Memorial Sloan Kettering Cancer Center (MSK) marks a potential advance against RAS-driven cancers; breaks down data silos to better predict cancer outcomes with the help of ...

Proteins that are commonly mutated and overexpressed in cancers are called oncoproteins and are typical targets for cancer therapies. Cancer treatment faces significant challenges due to the presence ...

Testing older potential organ donors for dangerous "zombie" cells could help to increase the number of hearts available for transplant, according to research presented at the British Cardiovascular ...

Researchers at the National Institutes of Health (NIH) and their collaborators have discovered a new way in which RAS genes, which are commonly mutated in cancer, may drive tumor growth beyond their ...